No Data
Emerging Markets Stock Digest: Micreed continues to rise, Sapeet hits the daily limit up.
<4883> Modaris 132 -14 consecutive decline. The stock price of the company has been sold due to the announcement by the Tokyo Stock Exchange on the 1st that the new initial selling and buying commission margin rates for the company's stock margin trading will be set at 50% or more (including cash portion of 20% or more). Moreover, Japan Securities Finance also announced the implementation of increased collateral collection measures, setting the collateral deposit rate for margin trading transactions for self-trading and non-settling participants at 50% (including cash collateral portion 20%) from the same day onwards.
Symbio Pharmaceuticals---Progress as planned for 3Q financial estimates.
Shinbiono Pharmaceutical <4582> announced its consolidated financial results for the third quarter of the fiscal year ending December 2024 (January-September 24). Revenue decreased by 57.1% year-on-year to 1.898 billion yen, operating loss was 2.791 billion yen (compared to a loss of 0.283 billion yen in the same period last year), ordinary loss was 2.759 billion yen (compared to a loss of 0.156 billion yen), and net quarterly loss attributable to the parent company's shareholders was 2.845 billion yen (compared to a loss of 0.788 billion yen). Currently, the Treacysin (R) intravenous infusion solution 100mg/4mL [
SymBio Pharmaceuticals: Summary of Financial Results for the 3rd Quarter Ending 2024/12 [Japanese GAAP] (Consolidated)
SymBio Pharmaceuticals 9-Mos Loss Y2.85B Vs Loss Y788.00M
SymBio Pharmaceuticals Sees FY Loss Y3.63B
Daiichi Sankyo, Fujitsu, JR East Japan, ANA (31st)
※The above calendar is subject to change depending on the company's schedule.---------------------------------------October 31st (Thursday) ＜1777＞Kawasaki Facilities ＜1798＞Morita Shokai ＜1911＞Sumitomo-Rin ＜1934＞Yuatec ＜1939＞Yondenko ＜1941＞Chudenko ＜1942＞Kandenko ＜1944＞Kinden ＜194
No Data
No Data